A SARS-CoV-2 Nanobody That Can Bind to the RBD Region May Be Used for Treatment in COVID-19 in Animals

Overview

Journal Res Vet Sci

Specialty Veterinary Medicine

Date 2022 Feb 13

PMID 35152188

Authors

Peng Wu

Qin Yang

Xiaoli Zhao

Qingqing Liu

Jing Xi

Fan Zhang

Jinke He

Hang Yang

Chao Zhang

Zhongchen Ma

Xiaoyu Deng

Yong Wang

Chuangfu Chen

Affiliations

Soon will be listed here.

Abstract

Coronavirus disease 2019 (COVID-19) caused by an infectious virus, severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2), poses a threat to the world. The suitable treatments must be identified for this disease in animals. Nanobody have therapeutic potential in the COVID-19. In this study, SARS-CoV-2 Spike RBD protein was used to make the nanobody. Nanobodies binding to the SARS-CoV-2 Spike RBD protein was obtained. Interestingly, the nanobody could bind to SARS-CoV-2 Spike S protein and RBD protein at the same time. Nanobodies were validated with a neutralizing antibody detection kit. The use of pseudoviruses confirmed that nanobodies could prevent pseudoviruses from infecting cells. We believe the nanobody are very valuable and could be used in the treatment of COVID-19. SARS-CoV-2 nanobodies can be rapidly mass-produced from microorganisms to block SARS-CoV-2 infection in vitro and in vivo with preventive and therapeutic effects.

Citing Articles

A scalable and high yielding SARS-CoV-2 spike protein receptor binding domain production process.

Riguero V, Delmar J, Dippel A, McTamney P, Luo E, Martinez A Protein Expr Purif. 2023; 205:106241.

PMID: 36736512 PMC: 9890279. DOI: 10.1016/j.pep.2023.106241.

A Review of Potential Therapeutic Strategies for COVID-19.

Meng J, Li R, Zhang Z, Wang J, Huang Q, Nie D Viruses. 2022; 14(11).

PMID: 36366444 PMC: 9696587. DOI: 10.3390/v14112346.

References

Jia Z, Liu C, Chen Y, Jiang H, Wang Z, Yao J . Crystal structures of the SARS-CoV-2 nucleocapsid protein C-terminal domain and development of nucleocapsid-targeting nanobodies. FEBS J. 2021; 289(13):3813-3825. PMC: 8646419. DOI: 10.1111/febs.16239. View

Czajka T, Vance D, Mantis N . Slaying SARS-CoV-2 One (Single-domain) Antibody at a Time. Trends Microbiol. 2021; 29(3):195-203. PMC: 7744031. DOI: 10.1016/j.tim.2020.12.006. View

Griffin B, Chan M, Tailor N, Mendoza E, Leung A, Warner B . SARS-CoV-2 infection and transmission in the North American deer mouse. Nat Commun. 2021; 12(1):3612. PMC: 8203675. DOI: 10.1038/s41467-021-23848-9. View

Olival K, Cryan P, Amman B, Baric R, Blehert D, Brook C . Possibility for reverse zoonotic transmission of SARS-CoV-2 to free-ranging wildlife: A case study of bats. PLoS Pathog. 2020; 16(9):e1008758. PMC: 7470399. DOI: 10.1371/journal.ppat.1008758. View

Wrapp D, De Vlieger D, Corbett K, Torres G, Wang N, Van Breedam W . Structural Basis for Potent Neutralization of Betacoronaviruses by Single-Domain Camelid Antibodies. Cell. 2020; 181(5):1004-1015.e15. PMC: 7199733. DOI: 10.1016/j.cell.2020.04.031. View

Lu Q, Zhang Z, Li H, Zhong K, Zhao Q, Wang Z . Development of multivalent nanobodies blocking SARS-CoV-2 infection by targeting RBD of spike protein. J Nanobiotechnology. 2021; 19(1):33. PMC: 7844813. DOI: 10.1186/s12951-021-00768-w. View

Koenig P, Das H, Liu H, Kummerer B, Gohr F, Jenster L . Structure-guided multivalent nanobodies block SARS-CoV-2 infection and suppress mutational escape. Science. 2021; 371(6530). PMC: 7932109. DOI: 10.1126/science.abe6230. View

Valenzuela Nieto G, Jara R, Watterson D, Modhiran N, Amarilla A, Himelreichs J . Potent neutralization of clinical isolates of SARS-CoV-2 D614 and G614 variants by a monomeric, sub-nanomolar affinity nanobody. Sci Rep. 2021; 11(1):3318. PMC: 7870875. DOI: 10.1038/s41598-021-82833-w. View

Xu J, Xu K, Jung S, Conte A, Lieberman J, Muecksch F . Nanobodies from camelid mice and llamas neutralize SARS-CoV-2 variants. Nature. 2021; 595(7866):278-282. PMC: 8260353. DOI: 10.1038/s41586-021-03676-z. View

10.

Pymm P, Adair A, Chan L, Cooney J, Mordant F, Allison C . Nanobody cocktails potently neutralize SARS-CoV-2 D614G N501Y variant and protect mice. Proc Natl Acad Sci U S A. 2021; 118(19). PMC: 8126837. DOI: 10.1073/pnas.2101918118. View

11.

Schoof M, Faust B, Saunders R, Sangwan S, Rezelj V, Hoppe N . An ultrapotent synthetic nanobody neutralizes SARS-CoV-2 by stabilizing inactive Spike. Science. 2020; 370(6523):1473-1479. PMC: 7857409. DOI: 10.1126/science.abe3255. View

12.

Esparza T, Martin N, Anderson G, Goldman E, Brody D . High affinity nanobodies block SARS-CoV-2 spike receptor binding domain interaction with human angiotensin converting enzyme. Sci Rep. 2020; 10(1):22370. PMC: 7755911. DOI: 10.1038/s41598-020-79036-0. View

13.

Ezzikouri S, Nourlil J, Tsukiyama-Kohara K, Kohara M, El Ossmani H, Windisch M . Nanobodies: an unexplored opportunity to combat COVID-19. J Biomol Struct Dyn. 2020; 40(7):3129-3131. PMC: 7678357. DOI: 10.1080/07391102.2020.1845801. View

14.

Kong Q, Yao Y, Chen R, Lu S . [Progress in nanobody and its application in diagnosis]. Sheng Wu Gong Cheng Xue Bao. 2015; 30(9):1351-61. View

15.

Saied A, Metwally A, Mohamed H, Haridy M . The contribution of bovines to human health against viral infections. Environ Sci Pollut Res Int. 2021; 28(34):46999-47023. PMC: 8284698. DOI: 10.1007/s11356-021-14941-z. View

16.

He T, Zhu J, Nie Y, Hu R, Wang T, Li P . Nanobody Technology for Mycotoxin Detection in the Field of Food Safety: Current Status and Prospects. Toxins (Basel). 2018; 10(5). PMC: 5983236. DOI: 10.3390/toxins10050180. View

17.

Sun Z, Chen C, Li W, Martinez D, Drelich A, Baek D . Potent neutralization of SARS-CoV-2 by human antibody heavy-chain variable domains isolated from a large library with a new stable scaffold. MAbs. 2020; 12(1):1778435. PMC: 7531518. DOI: 10.1080/19420862.2020.1778435. View

18.

Chi X, Liu X, Wang C, Zhang X, Li X, Hou J . Humanized single domain antibodies neutralize SARS-CoV-2 by targeting the spike receptor binding domain. Nat Commun. 2020; 11(1):4528. PMC: 7483421. DOI: 10.1038/s41467-020-18387-8. View

19.

Franklin A, Bevins S . Spillover of SARS-CoV-2 into novel wild hosts in North America: A conceptual model for perpetuation of the pathogen. Sci Total Environ. 2020; 733:139358. PMC: 7214292. DOI: 10.1016/j.scitotenv.2020.139358. View

20.

Ahmadvand D, Rahbarizadeh F, Vishteh V . High-expression of monoclonal nanobodies used in the preparation of HRP-conjugated second antibody. Hybridoma (Larchmt). 2008; 27(4):269-76. DOI: 10.1089/hyb.2008.0006. View